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Vasodilator Effect of Glucagon: Receptorial Crosstalk 
Among Glucagon, GLP-1, and Receptor for Glucagon 
and GLP-1
besides the activation of the cAMP-dependent 
protein kinase A (PKA), glucagon has also been 
shown to activate the extracellular signal-regu-
lated protein kinase 1/2 (ERK1/2) in a clonal cell 
line of human embryonic kidney cells [3]. The 
glucagon-induced activation of ERK 1/2 is known 
to be dependent on PKA activation [3].
It is well known that glucagon decreases vascular 
resistance in several organs, suggesting its vaso-
dilator effect, while the mechanism of the vaso-
dilator effect of glucagon is still unknown [4]. In 
strips of rabbit renal artery, the glucagon-
induced vasodilatation was dose-dependently 
inhibited by Ca2 + -antagonists, suggesting that its 
vasodilator effect evolves via the increase of 
intracellular calcium levels [4]. In rat renal arter-
ies in vivo, the vasodilator response to glucagon 
was shown to evoke with the contribution of 
nitric oxide (NO) [5].
Glucagon induces dose-dependent vasodilata-
tion in sympathetically-innervated arterial vas-
Introduction
▼
Glucagon, a 29 amino acid peptide hormone, 
produced by the α-cells of the pancreas, is mainly 
known for its role in the maintenance of blood 
glucose level, as it stimulates glycogenolysis and 
glyconeogenesis from pyruvate, lactate, glycerol, 
and some amino acids, thereby opposing the 
effects of insulin [1]. Various extra-hepatic 
effects of glucagon have been described, such as 
positive inotropic and chronotropic effects, while 
in the gastro-intestinal tract it acts as a smooth 
muscle relaxant, but it also affects the glomeru-
lar filtration rate, adipose tissue, thyroid gland, 
and the central nervous system [1, 2].
The effect of glucagon is known to evolve via the 
G-protein coupled glucagon-receptor, through 
the activation of adenylyl cyclase, increasing 
cyclic adenosine monophosphate (cAMP) levels, 
as well as activating the phospholipase C (PLC)/
protein kinase C (PKC) pathway [1, 2]. However, 
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Abstract
▼
Glucagon is known for its insulin-antagonist 
effect in the blood glucose homeostasis, while it 
also reduces vascular resistance. The mechanism 
of the vasoactive effect of glucagon has not been 
studied before; thereby we aimed to investigate 
the mediators involved in the vasodilatation 
induced by glucagon. The vasoactive effect of 
glucagon, insulin, and glucagon-like peptide-1 
was studied on isolated rat thoracic aortic rings 
using a wire myograph. To investigate the mecha-
nism of the vasodilatation caused by glucagon, 
we determined the role of the receptor for gluca-
gon and the receptor for GLP-1, and studied also 
the effect of various inhibitors of gasotransmit-
ters, inhibitors of reactive oxygen species forma-
tion, NADPH oxidase, prostaglandin synthesis, 
protein kinases, potassium channels, and an 
inhibitor of the Na + /Ca2 + -exchanger. Glucagon 
causes dose-dependent relaxation in the rat tho-
racic aorta, which is as potent as that of insulin 
but greater than that of GLP-1 (7–36) amide. 
Vasodilatation by GLP-1 is partially mediated by 
the glucagon receptor. The vasodilatation due to 
glucagon evokes via the glucagon-receptor, but 
also via the receptor for GLP-1, and it is endothe-
lium-independent. Contribution of gasotrans-
mitters, prostaglandins, the NADPH oxidase 
enzyme, free radicals, potassium channels, and 
the Na + /Ca2 + -exchanger is also significant. 
Glucagon causes dose-dependent relaxation of 
rat thoracic aorta in vitro, via the receptor for 
glucagon and the receptor for GLP-1, while the 
vasodilatation evoked by GLP-1 also evolves par-
tially via the receptor for glucagon, thereby, a 
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cular bed of dog liver in vivo; however, the vasodilator potential 
of glucagon was shown to be less remarkable, compared to that 
of other hormones (secretin, prostaglandin E2), and the onset of 
action was slow [6]. Glucagon decreases coronary vascular pres-
sure in isolated dog heart [7], while in isolated rat heart it poten-
tiates coronary reperfusion following ischemia, and increases 
NO production [8].
In traumatic brain injury, glucagon was shown to be protective 
against impaired cerebrovasodilation via the activation of the 
cAMP-PKA pathway [9], while besides the upregulation of cAMP, 
another study demonstrated that the inhibition of the ERK and 
mitogen activated protein kinase (MAPK) pathway by glucagon 
also contributes to its protective effect [10].
Despite the number of studies investigating the mechanism of 
the glucagon-induced decrease in vascular resistance, the pre-
cise mechanism of the vasodilatation regarding the gaseous 
mediators, protein kinases and ion channels, remains unclear. 
Here we aimed to demonstrate that glucagon induces dose-
dependent vasodilatation of the isolated rat thoracic aorta, and 
also aimed to determine the gaseous mediators that activate the 
protein kinases and ion channels involved in the vasodilatation 
evoked by glucagon using a wire myograph. We aimed to inves-
tigate whether GLP-1 and glucagon are able to cross-activate 




Experiments were performed with the permission of the Hun-
garian Local Animal Experiment Committee in accordance with 
the ‘Principles of laboratory animal care’ (NIH publication no. 
85–23, revised 1985). Male Sprague-Dawley rats (Charles River 
Laboratories GmbH, Sulzfeld, Germany), 10–12 week old, weigh-
ing 280–340 g, were kept on standard chow ad libitum with con-
tinuous water supply. On the day of the experiment rats were 
killed in diethyl ether narcosis by decapitation.
Vasoreactivity experiments
The rat thoracic aorta was gently excised and placed in oxygen-
ated (95 % O2/5 % CO2), ice-cold Krebs solution (119 mM NaCl, 
4.7 mM KCl, 1.2 mM KH2PO4, 25 mM NaHCO3, 1.2 mM MgSO4, 
11.1 mM glucose, 1.6 mM CaCl2 · 2H2O, pH 7.4). Vessels were 
carefully cleaned from perivascular fat and connective tissue as 
described earlier [11, 12], and cut into 2 mm long segments. The 
vessel rings were mounted on 2 stainless steel wires (40 µm in 
diameter), and placed in 5 ml organ baths of a wire myograph 
(Danish Multimyograph Model 610M, DMT-USA Inc., Atlanta, 
GA, USA). Aortic rings were kept in continuously oxygenated 
Krebs solution (37 °C, pH 7.4) and placed under a tension of 1 g 
[13]. Isometric tension was continuously recorded. After 30 min 
rest, aortic rings were preconstricted with 100 nM epinephrine 
as described earlier [13, 14], which in our previously performed 
experiments had shown 60 % contraction force of the 60 mM KCl 
contraction [14]. When all vessel segments had reached a stable 
contraction plateau, increasing doses (0.1, 1, 2.5, 10, 25 µM) of 
glucagon (Sigma-Aldrich, St. Louis, MO, USA) were administered 
to the organ baths, and relaxant responses were assessed (n = 6). 
The Kd50 value for the activation of the glucagon receptor is in 
the nanomolar range [15], while the applied dosages of glucagon 
were adjusted to the dose of epinephrine that we used to pre-
constrict the vessels. Plasma epinephrine level is approximately 
30 pM at rest, while in our experiments we used 100 nM, which 
is a clear supraphysiological concentration [16]. Since the dose 
of epinephrine needed to be increased to achieve sufficient pre-
constriction, also the applied doses of glucagon needed to be 
increased accordingly.
In one set of experiments, the vasodilator efficacy of glucagon, 
insulin and glucagon-like peptide-1 amide fragment (7–36) 
[GLP-1 (7–36)] was compared (n = 4). In another experiment, the 
endothelium of the vessels was mechanically removed by gently 
rubbing a hair through it (n = 5). The effect of denudation was 
verified by the loss of response to 3 µM acetylcholine. A series of 
experiments were performed in order to identify the extracel-
lular and intracellular mediators of the vasodilator effect of 
glucagon (n = 4). Prior to contracting the vessels with epineph-
rine, vessels were preincubated with different materials (n = 4 
for each experiment). To determine whether the vasodilatation 
due to glucagon evoked via the glucagon-receptor, in one set of 
experiments vessels were preincubated with a specific glucagon 
receptor antagonist (hGCGR-antagonist; Sigma-Aldrich, St. Louis, 
MO, USA) (25 µM, 30 min) (n = 4). To investigate whether the 
glucagon-like peptide-1-receptor (GLP-1R) is involved in the 
vasodilatation evoked by glucagon, vessels were preincubated 
with the GLP-1R antagonist exendin (9–39) (25 µM, 30 min, 
n = 4). To test the hypothesis, that GLP-1 might induce vasodila-
tation via the glucagon-receptor, some vessels were incubated 
with hGCGR-antagonist (75 µM, 30 min, n = 4), prior to perform-
ing the experiment with GLP-1 (7–36).
A group of vessels were incubated with the eNOS inhibitor 
L-NAME (300 µM, 30 min, n = 4). Other vessels were incubated 
with the potent heme oxygenase inhibitor tin protoporphyrin IX 
dichloride (10 µM, 30 min, n = 4), others with dl-propargylgly-
cine, inhibitor of cystathionine-γ-lyase (10 mmol/l, 30 min, 
n = 4), or with the relatively selective cyclooxygenase-1 (COX-1) 
inhibitor indomethacin (3 µM, 30 min, n = 4).
We tested the effects of superoxide dismutase (SOD; 200 U/ml, 
30 min, n = 4) and catalase (1 000 U/ml, 30 min, n = 4). The contri-
bution of the NADPH oxidase enzyme was demonstrated by 
inhibiting it with diphenyleneiodonium chloride (DPI) (10 µM, 
30 min, n = 4). H89 hydrochloride (5 µM, 30 min, n = 4) was used 
to inhibit PKA and 1H-1,2,4-oxadiazolo(4,3-a)quinoxalin-1-one 
(ODQ, 3 µM, 30 min, n = 4) was used to inhibit the effect of solu-
ble guanylyl cyclase (sGC).
To block the large-conductance calcium-activated potassium 
channels (BKCa channels) some vessels were incubated with 
tetraethylammonium bromide (TEA, 2 mM, 30 min, n = 4) for 
30 min [15]. To block the ATP-sensitive potassium channels 
(KATP), we used glibenclamide (10 µM, 30 min, n = 4) [17]. KCNQ-
type voltage-dependent potassium channels were blocked by 
incubation with XE991 (30 µM, 15 min, n = 4) [12]. The Na + /
Ca2 + -exchanger was blocked by incubation with its specific 
inhibitor SEA0400 (4 µM, 30 min, n = 4) [18].
Untreated time-control experiments were performed to exclude 
spontaneous vessel relaxation; however, it was not significant. To 
test the effect of the specific inhibitors on the permanence of the 
epinephrine-induced plateau, we performed a row of control 
experiments, and found that most of the chemicals had a slight 
vasodilator effect, which could not have a significant influence on 
the results (Effect on the epinephrine-induced plateau: untreated 
control: 1.02 ± 1.09 %; hGCGR-antagonist: 3.56 ± 2.07 %); exendin 
(9–39): 3.35 ± 3.07 %; L-NAME: 4.72 ± 2.34 %; tin protoporphyrin: 
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10.28 ± 1.99 %; PPG: 5.28 ± 4.00 %; indomethacin: 10.28 ± 2.56 %; 
SOD: 1.78 ± 0.94 %; catalase: 1.45 ± 0.80 %; DPI: 2.15 ± 0.34 %, H89: 
9.05 ± 2.82 %; ODQ: 5.21 ± 4.34 %; TEA: 10.69 ± 4.39 %; glibencla-
mide 4.34 ± 1.02 %; XE991: 6.62 ± 4.50 %; SEA0400: 2.32 ± 1.64 %, 
data represent mean ± SD).
The effect of the inhibitors on the epinephrine-induced contrac-
tion was also studied; however, no statistical significance could 
be shown. We compared the effect of inhibitors on the magni-
tude of the epinephrine-induced contraction with the magni-
tude of the epinephrine-induced contraction in the control 
experiments. (The level of constriction in % of maximum con-
striction of the vessel studied: control: 100 ± 21.32 %, hGCGR-
antagonist: 109.67 ± 14.44 %); exendin (9–39): 66.13 ± 4.12 %; 
L-NAME: 104.03 ± 11.71 %; tin protoporphyrin: 79.16 ± 10.25 %; 
PPG: 90.53 ± 12.93 %; indomethacin: 97.73 ± 15.72 %; SOD: 
74.32 ± 4.00 %; catalase: 61.65 ± 20.02 %; DPI 69.93 ± 6.79 %, H89: 
90.2 ± 15.13 %; ODQ: 105.61 ± 12.14 %; TEA: 112.51 ± 25.39 %; 
glibenclamide 89.01 ± 17.68 %; XE991: 74.33 ± 9.62 %; SEA0400: 
97.65 ± 25.75 %, data represent mean ± SD).
Chemicals were purchased from Sigma-Aldrich, St. Louis, MO, 
USA, except for tin protoporphyrin IX dichloride, which was pur-
chased from Santa Cruz Biotechnology (Dallas, Texas, USA); 
XE991 was purchased from Ascent Scientific Ltd. (Avonmouth, 
Bristol, UK), while epinephrine was purchased from Richter-
Gedeon Hungary (Budapest, Hungary). SEA0400 was synthe-
sized in the Institute of Pharmaceutical Chemistry, University of 
Szeged, Hungary by Professor Ferenc Fülöp.
Myodaq 2.01 M610 + software was used for data acquisition and 
display. We expressed the rate of relaxation caused by glucagon, 
GLP-1, and insulin as the percentage of the contraction evoked 
by epinephrine.
Statistical analysis
Statistical analysis was performed by using SPSS Version 22.0 
(SPSS Inc., Chicago, IL, USA) and GraphPad Prism 6.0 (GraphPad 
Software Inc., La Jolla, CA, USA). Statistical significance was cal-
culated using repeated measures ANOVA with Bonferroni post-
hoc test in case of the dose-response curves. Log EC50 values 
showed non-normal distribution, therefore, nonparametric tests 
were used (Kruskal-Wallis test followed by Mann-Whitney test). 
Values are shown as mean ± SD. A value of p less than 0.05 was 
considered to be significant.
Results
▼
Glucagon induces endothelium-independent 
vasodilatation of the rat aorta, comparable to the 
vasodilatation caused by insulin and GLP-1
Glucagon caused dose-dependent vasodilatation of the rat tho-
racic aorta, which was as effective as the vasodilatation evoked 
by insulin. Glucagon and insulin proved to be more potent 
 vasodilators in the rat thoracic aorta than native GLP-1 (7–36) 
( ●▶  Fig. 1a). Log EC50 values for the glucagon-induced vasodilata-
tion were not significantly different from that of insulin, [median 
(IQR) log EC50 values − 5.336 (0.27); − 5.313 (0.21); respectively, 
p = 0.958]; while it was significantly lower than that of GLP-1, 
[− 5.336 (0.27) vs. − 4.385 (0.27), p = 0.003].
Vessels with mechanically damaged endothelium showed no 
decrease in the vasodilator response to glucagon, moreover, the 
vasodilatation in endothelium-denuded vessels was more pro-
nounced than that in endothelium-intact vessels [log EC50 val-
ues − 5.336 (0.27) vs. − 4.78 (0.21) p = 0.013] ( ●▶  Fig. 1b). However, 
the low number of cases limits the interpretation of these findings.
Glucagon causes vasodilatation via the receptor for 
glucagon and GLP-1
Inhibition of the glucagon-receptor with its antagonist signifi-
cantly decreased the vasodilator response to glucagon ( ●▶  Fig. 1c). 
On the other hand, GLP-1R inhibition with its specific antago-
nist, exendin (9–39) also caused a significant reduction in the 
vasodilatation caused by glucagon ( ●▶  Fig. 1d). However, the 
effect of the glucagon receptor blocker was more pronounced 
than that of the GLP-1 receptor blocker.
Fig. 1 Concentration-relaxation curves represent-
ing a comparison of the vasodilator potential of 
glucagon, insulin and GLP-1 (7–36) amide a. Role 
of the endothelium in the vasodilatation evoked by 
glucagon b. Receptors in the vasodilator effect of 
glucagon and GLP-1: effect of a glucagon receptor 
antagonist (hGCGR-antagonist) c and GLP-1R inhi-
bition by the receptor antagonist exendin (9–39) 
d. Inhibition of the GLP-1 induced vasodilatation 
by glucagon receptor blockade e. n = 4, * p < 0.01 
compared to the relaxation evoked by glucagon 
only (at respective concentration of glucagon).
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Glucagon-like peptide-1 causes vasodilatation via the 
glucagon-receptor
The concentration-dependent vasorelaxation caused by GLP-1 
(7–36) amide was significantly reduced in vessels preincubated 
with a glucagon-receptor antagonist (hGCGR-antagonist) ( ●▶  Fig. 1e), 
although the glucagon receptor blocker inhibited the GLP-1-in-
duced vasodilatation only at smaller concentrations, but it did 
not inhibit the vasodilatation when the highest dosage of GLP-1 
was applied.
Contribution of gasotransmitters and the effect of COX-1 
inhibition in the vasodilatation evoked by glucagon
Inhibition of NO production with the eNOS inhibitor L-NAME 
significantly inhibited vasodilatation when lower dosages of 
glucagon were applied, however, it had no effect when higher 
concentrations of glucagon were used ( ●▶  Fig. 2a). The blockade 
of CO formation with the heme oxygenase inhibitor tin proto-
porphyrin ( ●▶  Fig. 2b) and the inhibition of the H2S generating 
cystathionine-γ-lyase with dl-propargylglycine ( ●▶  Fig. 2c) both 
significantly inhibited the vasodilator effect of glucagon. Prosta-
glandin synthesis inhibition with indomethacin resulted in a 
significantly reduced vasodilatation to glucagon ( ●▶  Fig. 2d).
Involvement of NADPH oxidase enzyme in the 
vasodilatation induced by glucagon
Glucagon-induced vasodilatation was significantly decreased 
when vessels were preincubated with superoxide dismutase 
( ●▶  Fig. 2e), or catalase ( ●▶  Fig. 2f), or the NADPH oxidase inhibitor 
DPI ( ●▶  Fig. 2g).
Role of protein kinase G and protein kinase A in the 
vasodilation caused by glucagon
Soluble guanylyl cyclase inhibitor ODQ almost completely abol-
ished the vasodilator effect of glucagon ( ●▶  Fig. 3a). Using H89, an 
inhibitor of PKA, the vasodilator response to glucagon signifi-
cantly decreased ( ●▶  Fig. 3b).
Role of ion channels and transporters in the vasodilator 
effect of glucagon
Blockade of the large-conductance calcium-activated potassium 
channels by TEA significantly reduced the vasodilatation induced 
by glucagon ( ●▶  Fig. 3c). ATP-sensitive potassium channels were 
blocked with glibenclamide, which almost entirely abolished 
the vasodilatation in response to glucagon ( ●▶  Fig. 3d). KCNQ-
type Kv channel inhibition by XE991 ( ●▶  Fig. 3e) also significantly 
reduced the vasodilator effect of glucagon.
Inhibition of the NCX with SEA0400 significantly decreased the 
vasodilatation evoked by glucagon ( ●▶  Fig. 3f).
Discussion
▼
The major novel findings of this study are as follows: glucagon 
dose-dependently relaxes the rat thoracic aorta in vitro. The 
vasodilator potential of glucagon is the same as that of insulin 
and it is greater than that of GLP-1 (7–36) amide. The vasodilata-
tion in response to glucagon evokes mostly via the glucagon-
receptor, but it is also mediated by the GLP-1R. GLP-1 (7–36) 
amide also dilates the rat thoracic aorta, which is partially medi-
ated by the glucagon receptor. According to our findings the fur-
ther mediators of the vasodilatation evoked by glucagon are 
Fig. 2 Concentration-relaxation curves showing 
the possible role of gasotransmitters and pros-
taglandins in the vasodilator effect of glucagon: 
eNOS inhibition with Nω-nitro-l-arginine methyl 
ester hydrochloride (L-NAME) a. Blocking CO 
production via the inhibition of the enzyme heme 
oxygenase with tin protoporphyrin IX dichloride 
b. Inhibition of H2S production by inhibiting 
cystathionine-γ-lyase with dl-propargylglycine 
(PPG) c. Inhibition of prostaglandin synthesis 
with indomethacin d. Concentration-relaxation 
curves of glucagon alone and with the addition of 
catalase e, and superoxide dismutase (SOD) f or 
NADPH oxidase inhibition with diphenyleneiodo-
nium chloride (DPI) g. n = 4, p < 0.01 compared to 
the relaxation evoked by glucagon only (at respec-
tive concentration of glucagon).
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gasotransmitters, prostaglandins and free radicals, mainly H2O2, 
thereby activating the NADPH oxidase enzyme and the soluble 
guanylyl cyclase and PKA, resulting in the activation of potas-
sium channels and finally the NCX, which leads to smooth mus-
cle relaxation, hence vasodilatation ( ●▶  Fig. 4).
Decreased vascular resistance and relaxation of hepatic and 
other, peripheral arteries has formerly been attributed to gluca-
gon [4–8], however, the precise description of the vasodilator 
mechanism of glucagon has so far not been given.
Metabolic actions of glucagon evolve via the glucagon-receptor 
[1], however, it has not been verified, whether its vasodilator 
effect is transmitted by the glucagon receptor. Here we demon-
strate that glucagon induces vasodilatation via the activation of 
both the glucagon- and the glucagon-like peptide-1-receptor 
(GLP-1R). Moreover, we reveal that the glucagon-receptor is also 
responsible, at least partially, for the GLP-1-induced vasodilata-
tion. According to our experiments, GLP-1 induces vasodilatation 
via the glucagon receptor, but at higher concentrations of GLP-1 
the vasodilatation does not evoke via the glucagon receptor.
Our findings are in contrast with previous experiments, where 
in other cell lines GLP-1 did not cross-react with the glucagon-
receptor, however, a cross-reactivity of glucagon on the GLP-1 
receptor occurred only at 1000-fold higher concentrations than 
that of GLP-1 [19].
These 2 receptors are homologous G-protein coupled receptors 
[20]. A study with chimeric glucagon/GLP-1 peptides proved 
that the major determinant of the glucagon/GLP-1 selectivity of 
the receptor is the amino-terminal of the extracellular domain 
of the GLP-1R [20]. The homology of these receptors might be 
the reason for the cross-talk of the glucagon-and GLP-1-induced 
vasodilatation. Type 2 diabetes is commonly treated by ana-
logues of native GLP-1 and dipeptidyl peptidase-4 (DPP-4) 
inhibitors, inhibitors of the enzyme degrading incretin hor-
mones (GLP-1 and GIP), thereby elevating the level of GLP-1 [21]. 
As a recent study pointed out, GLP-1 agonists might also be used 
off-label to promote weight loss in obese patients without dia-
betes [22].
These drugs are also known to decrease glucagon level [21]. 
Alike GLP-1, its analogues also cause vasodilatation [13]. Specu-
latively, based on our novel findings, the drugs that increase 
GLP-1 level, might also induce vasodilatation via the glucagon 
receptor. Moreover, glucagon and its receptors have been sug-
gested to be potential targets for the treatment of type 2 diabe-
tes and its complications [23].
Also GLP-1 and other related peptides are known to induce 
vasodilatation in central as well as peripheral vessels, but the 
mechanism of action differs in the different parts of the arterial 
tree [13, 24–28]. Native GLP-1 dilates rat thoracic aorta and fem-
oral artery in an endothelium-independent manner, and at the 
same time independent of nitric oxide production in vitro 
[24, 25], while in the rat pulmonary arteries the vasodilatation 
induced by GLP-1 is endothelium-dependent [26].
Both GLP-1R-dependent and -independent vasodilator mecha-
nisms of GLP-1 mimetics have been described [13, 28]. In 
Glp1r − / −  mice, native GLP-1 reduced the ischemic damage after 
ischemia-reperfusion and also increased the production of 
cGMP, thereby leading to vasodilatation, and increased coronary 
flow [28]. However, the same study reported GLP-1R-dependent 
cardioprotective and glycemic effects of native GLP-1 amide [28]. 
It has also been suggested that GLP-1 peptides induce vascular 
relaxation in a GLP-1R-independent manner, at least in the rat 
aorta, independently of its well-known metabolic actions [24].
Although the presence of glucagon receptors on hepatocytes is 
well known, their density is increased following exercise in fast-
ing in rats [29], and the presence of GLP-1 receptors on hepato-
cytes is not so evident [1, 30]. Despite this fact, increasing 
number of evidences indicate, that among their pleotropic 
effects, GLP-1 analogues have a beneficial effect on liver function 
[31–33]. Liraglutide, a long acting GLP-1 analogue, decreases 
lipotoxicity as well as increases hepatic insulin sensitivity in 
nonalcoholic steatohepatitis (NASH) [30]. Another study also 
demonstrated, that liraglutide significantly improved liver func-
tion and histological features in NASH patients with glucose 
intolerance [32]. Liraglutide and exenatide, another GLP-1 ago-
Fig. 3  Effector molecules in the vasodialata-
tion induced by glucagon: Inhibition of soluble 
guanylyl cyclase with 1H-(1,2,4)oxadiazolo [4,3–α]
quinoxalin-1-one (ODQ) a. cAMP-dependent 
protein kinase A(PKA) blockade with H89 hydro-
chloride b. Involvement of potassium channels and 
the Na + /Ca2 + -exchanger in the vasodilator effect 
of glucagon: Inhibition of the large-conductance 
calcium-activated potassium channels with 
tetraethylammonium (TEA) c. Blockade of the ATP-
sensitive potassium channels with glibenclamide 
d. KCNQ-type Kv channels were blocked by XE991 
e. Selective inhibition of the Na + /Ca2 + -exchanger 
with SEA0400 f. n = 4, * p < 0.01 compared to the 
relaxation evoked by glucagon only (at respective 
concentration of glucagon).
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nist, were shown to improve transaminase levels as well as his-
tology in patients with NASH [33]. Sitagliptin, an inhibitor of the 
DPP-4 enzyme, also showed improvement in transaminases 
[33]. The possibility that GLP-1 receptor agonists may cross-acti-
vate glucagon receptors, for example, on the hepatocytes, could 
explain this beneficial effect of the GLP-1 agonist drugs.
Our novel finding might be one of the underlying mechanisms 
explaining the pleotropic effects of GLP-1, as we have demon-
strated that GLP-1 activates the glucagon-receptors as well, 
moreover, glucagon also acts on GLP-1 receptors. For instance, a 
dissociation of endocrine and metabolic effects of the Roux-en-Y 
gastric bypass operation was found in a mildly obese patients 
with type 2 diabetes, namely, when compared to the preopera-
tive meal tolerance test, after the operation, no increase of GLP-1 
and insulin secretion, but improved hepatic and peripheral insu-
lin sensitivity were found [34].
Another pleotropic effect of GLP-1 may be the recently described 
stimulation of the expression of a novel insulin-mimetic adipo-
cytokine, visfatin, via the PKA pathway, which might also influ-
ence glucose metabolism [35].
Insulin was also previously shown to induce vasodilatation via 
increasing NO production through the phosphatidylinositol 
3-kinase/Akt (PI3K/Akt) pathway [36, 37]. However, insulin was 
also shown to cause vasoconstriction via the MAPK pathway via 
inducing the production of endothelin-1 [38]. A pathway-spe-
cific impairment in phosphatidylinositol 3-kinase-dependent 
signaling is present in insulin resistance, thereby contributing to 
the endothelial dysfunction [38].
Similar to the signal transduction of insulin, PI3K/Akt is also 
involved in the effect of glucagon together with the cAMP/PKA, 
PLC/PKC and ERK, MAPK pathways [3]. We demonstrated the 
role of PKA and the sGC-cGMP-protein kinase G pathway in the 
vasodilatation induced by glucagon.
The role of NO and prostaglandins in the glucagon-induced 
vasodilatation have previously been presented [5], but we went 
further and reveal that all of the 3 gasotransmitters, NO, hydro-
gen sulfide (H2S), and carbon monoxide (CO), prostaglandins 
and reactive oxygen species (ROS)-superoxide anion (O2 − •) and 
hydrogen peroxide (H2O2) are parts of the vasodilatation induced 
by glucagon. Production of ROS is mediated by the NADPH oxi-
Fig. 4 Hypothetical mechanism of the vasodila-
tion induced by glucagon. NO: Nitric oxide; H2S: 
Hydrogen sulfide; CO: Carbon monoxide; O2 − •: 
Superoxide anion; H2O2: Hydrogen peroxide, PKA: 
cAMP-dependent protein kinase; PKG: cGMP-de-
pendent protein kinase, SMC: Smooth muscle cell.
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dase, while these products may activate the sGC-cGMP-PKG 
pathway, leading to vasodilatation.
Potassium channels are frequently targets of gasotransmitters, 
thereby leading to vasodilatation [17]. Glucagon activates the 
ATP-sensitive – the large-conductance calcium –activated and 
the KCNQ-type voltage-gated potassium channels and causes 
vasorelaxation.
The terminal effector of the glucagon-induced vasodilatation 
according to our experiments is the Na + /Ca2 + -exchanger, which 
is a transmembrane protein, regularly extruding calcium with a 




Glucagon may activate both the glucagon- and the GLP-1-recep-
tor, thereby leading to dose-dependent, endothelium-independ-
ent vasodilatation with the contribution of the NADPH oxidase 
enzyme, free radicals, gasotrasmitters, prostaglandins, PKA, 
sGC, potassium channels, and finally the NCX.
Limitations of our study are the use of a single methodology 
(myography) and the absence of in vivo experiments, and the 
specificity of the inhibitors.
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